{"entity":{"id":"nct06839066","kind":"trial","name":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","aka":[],"tldr":"A phase 2 trial of HLX43 DOSE 1 in nasopharyngeal carcinoma, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy is a phase 2 interventional study registered as NCT06839066 by Shanghai Henlius Biotech, with 70 participants planned, started 2025-04-02 and due to reach its primary completion in 2026-11-22. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06839066","url":"https://clinicaltrials.gov/study/NCT06839066"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nasopharyngeal","recurrent-metastatic-nasopharyngeal-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06839066","phase":"2","setting":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma (NPC) Failed or Intolerance to Second-line Therapy","sponsor":"Shanghai Henlius Biotech","participation":[{"nct":"NCT06839066","source":"https://clinicaltrials.gov/study/NCT06839066","fetchedAt":"2026-10-07T16:55:09.829Z","studySha256":"a10947a46379c670db6c8a07596b9d90cdf648d8ae0f55aaa44ade901271b48a","overallStatus":"RECRUITING","lastUpdatePosted":"2025-11-24","leadSponsor":"Shanghai Henlius Biotech","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":15,"recruitingSiteCount":15,"countries":["China"]}],"started":"2025-04-02","startedType":"actual","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06839066/","neighbours":{"cancer":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}